A disease associated with
immunoglobulin IgG4 is a rare unit with very variable symptoms. We describe the course and treatment of the disease in a patient who presented with multiple
lymphadenopathy and infiltrates in the area of the retroperitoneum and pelvis and signs of chronic sclerosing
pancreatitis. The disease was clinically manifested by a significant loss of weight, but also by a loss of perception of taste and smell. The diagnosis was made based on a high amount of
IgG4 expressing plasma cells in the sampled tissue and an increased concentration of
immunoglobulins of type
IgG and mainly subclass IG4.
Rituximab in 475 mg/m2 dose was used in the treatment, the initial four doses of
rituximab were administered at 14-day intervals, always with a one-off administration of a 40 mg dose of
dexamethasone. According to FDG-PET/CT, only partial remission of the disease was reached after 4 applications of
rituximab and
dexamethasone. The patient recovered its sense of smell and taste. In another 4 cycles ritu-ximab was administered on day 1 of a 28-day cycle. On days 1 and 15 of the cycle
dexamethasone at 40 mg and
cyclophosphamide at 600 mg were administered by
intravenous infusion. After the completion of 8 cycles of treatment based on
rituximab and
dexamethasone and with
cyclophosphamide added in the second half of the treatment, the control FDG-PET/CT examination proved the complete remission. Before the treatment commencement the concentration of the subclass of
immunoglobulin IgG4 was equal to 51.0 g/l, after the completion of the aforementioned treatment it dropped to 3.5 g/l. The patient tolerated the treatment without any adverse effects. Ritu-ximab,
dexamethasone and
cyclophosphamide induced the complete remission of this disease.Key words:
IgG4-associated/releated disease -
rituximab.